

**CHANGE OF STATUS REPORT
SECTION 11.2 OF NATIONAL INSTRUMENT 51-102**

**To: British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Ontario Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Nova Scotia Securities Commission
Office of the Attorney General (Prince Edward Island)
Securities NL, Financial Services Regulation Division, Department of Government Services**

Pursuant to Section 11.2 of National Instrument 51-102 – *Continuous Disclosure Obligations*, Mydecine Innovations Group Inc. (the “**Corporation**”) reports that on March 23, 2021, the Corporation’s common shares and share purchase warrants commenced trading on the Aequis Neo Exchange under the symbols MYCO and MYCO.WT, respectively, and ceased trading on the Canadian Securities Exchange. As a result, the Corporation ceased to be a “venture issuer”, as that term is defined under National Instrument 51-102.

Dated this 21st day of April, 2021.

MYDECINE INNOVATIONS GROUP INC.

By: (s) David Joshua Bartch
Name: David Joshua Bartch
Title: Chief Executive Officer